Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-252

Yes, you are right, my friend - we certainly do need to wait for more updates, but we have data now, so let's keep focused on that.

The reason I like using the ICI data is that it involves multiple cancer types, like what has been included in the basket P1 data and surely what cohort 4 consist of.

I'm interested to know what your thoughts are about why the iCR is stated for the cholangiocarcinoma patient, but no other outcomes are stated?

This is good work, mate. The issue with your conclusion is that it is unknown how many patients that had iUPD (an increase in tumor size which required further evaluation), which was later confirmed as PD or SD. The study you are referring to had an ORR of 26%. Half of those people (13%) had pseudoprogression. Pseudoprogression being an initial increase in tumor size, which then eventually leads to a response (CR/PR). This is the highest % of a population that has been recorded in the literature and it focuses on a single cancer type. It's up to you whether you want to use this to determine risk.

@Jase99 and @James5656 have you found pseudoprogression response rates for unapproved OV therapies in advanced solid tumors? Also, I'm interested in what your % chance of success might be for the cohort 4 patients.